一种非甾体抗炎药（氟比洛芬）用于控制对饮食调整耐药的特发性高钙尿症。

A non-steroidal anti-inflammatory drug (flurbiprofen) to control idiopathic hypercalciuria resistant to dietary manipulation.

作者信息

Rao P N, Blacklock N J

出版信息

Br J Urol. 1983 Dec;55(6):599-602. doi: 10.1111/j.1464-410x.1983.tb03384.x.

DOI:10.1111/j.1464-410x.1983.tb03384.x

Abstract

Twenty-three calcium stone formers with idiopathic hypercalciuria were entered into an open study to examine the effects of flurbiprofen (Froben) on urinary calcium excretion. Five patients were withdrawn because of side effects. A statistically significant reduction in urinary calcium excretion was noted after 2 (P = 0.004) and 6 (P = 0.001) weeks' treatment. There was a significant increase in urinary calcium excretion after stopping the treatment (P = 0.0006). The results suggest that flurbiprofen reduces calcium excretion in the urine but the high incidence of side effects may limit its use in routine treatment of hypercalciuria.

摘要

23名患有特发性高钙尿症的含钙结石患者参与了一项开放性研究，以检验氟比洛芬（氟联苯丙酸）对尿钙排泄的影响。5名患者因副作用退出研究。治疗2周（P = 0.004）和6周（P = 0.001）后，尿钙排泄量出现了具有统计学意义的下降。停止治疗后，尿钙排泄量显著增加（P = 0.0006）。结果表明，氟比洛芬可减少尿钙排泄，但副作用发生率较高，这可能会限制其在高钙尿症常规治疗中的应用。